Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHMT2 | P34897 | 4/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | AKT1 | P31749 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | GPR183 | P32249 | 1/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.44 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15546417 | 0.83 | NPC1 (0.69) | L3MBTL1RAB9ANPC1MAPTPOLB | |
| SCHEMBL18770242 | 0.81 | MAOA (0.46) | SHMT2L3MBTL1AKT1RAB9ANPC1 | |
| SCHEMBL11026657 | 0.77 | MAPT (0.70) | RAB9ANPC1ATMMAPTPOLB | |
| SCHEMBL20702982 | 0.75 | ALDH1A1 (0.54) | RAB9ANPC1ATMMAPTALDH1A1 | |
| SCHEMBL21999408 | 0.75 | PDE3B (0.43) | SHMT2L3MBTL1PIK3CBALDH1A1 | |
| SCHEMBL15545383 | 0.74 | MAPT (0.68) | L3MBTL1RAB9ANPC1MAPTPOLB | |
| SCHEMBL16583835 | 0.73 | MAPT (0.60) | L3MBTL1AKT1RAB9ANPC1MAPT | |
| SCHEMBL18787217 | 0.72 | PRKDC (0.57) | L3MBTL1RAB9ANPC1ATMMAPT | |
| SCHEMBL20467962 | 0.71 | NPC1 (0.54) | SHMT2RAB9ANPC1MAPTPOLB | |
| SCHEMBL23962394 | 0.71 | ATM (0.60) | L3MBTL1ATMMAPTPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2875001-B1 | NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS | SUNSHINE LAKE PHARMA CO LTD (CN) | 2019-01-09 | — | — | EP | disclosed |
| US-9434695-B2 | Nitrogenous heterocyclic derivatives and their application in drugs | SUNSHINE LAKE PHARMA CO., LTD (CN) | 2016-09-06 | — | — | US | disclosed |
| EP-2875001-A1 | NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS | Sunshine Lake Pharma Co., Ltd. (CN) | 2015-05-27 | — | — | EP | disclosed |
| US-20150087639-A1 | Nitrogenous Heterocyclic Derivatives And Their Application In Drugs | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-03-26 | — | — | US | disclosed |
| WO-2014012360-A1 | NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2014-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087639-A1 | Nitrogenous Heterocyclic Derivatives And Their Application In Drugs | TNNC1, TNNI3, IAPP | SHMT2 106/4885L3MBTL1 3927/4885AKT1 1123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.